Home » Stocks » Biospecifics Technologies

Biospecifics Technologies Corp. (BSTC)

Stock Price: $63.87 USD -0.44 (-0.68%)
Updated Aug 4, 2020 3:29 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 469.12M
Revenue (ttm) 39.73M
Net Income (ttm) 24.55M
Shares Out 7.34M
EPS (ttm) 3.34
PE Ratio 19.12
Forward PE 30.58
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $63.87
Previous Close $64.31
Change ($) -0.44
Change (%) -0.68%
Day's Open 64.32
Day's Range 62.39 - 64.76
Day's Volume 25,399
52-Week Range 42.00 - 69.51

More Stats

Market Cap 469.12M
Enterprise Value 365.13M
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 7.34M
Float 4.31M
EPS (basic) 3.36
EPS (diluted) 3.34
FCF / Share 3.33
Dividend n/a
Dividend Yield n/a
Earnings Yield 5.23%
FCF Yield 5.20%
Payout Ratio n/a
Shares Short 298,977
Short Ratio 7.08
Short % of Float 4.55%
Beta 0.90
PE Ratio 19.12
Forward PE 30.58
P/FCF Ratio 19.23
PS Ratio 11.81
PB Ratio 3.56
Revenue 39.73M
Operating Income 28.47M
Net Income 24.55M
Free Cash Flow 24.40M
Net Cash 103.99M
Net Cash / Share 14.16
Gross Margin 96.12%
Operating Margin 71.67%
Profit Margin 61.80%
FCF Margin 61.41%
ROA 15.48%
ROE 21.21%
ROIC 28.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$100.00*
Low
100
Current: $63.87
High
100
Target: 100.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue38.1932.9627.4426.2522.7514.0414.4311.1511.405.66
Revenue Growth15.86%20.11%4.54%15.39%61.98%-2.67%29.47%-2.2%101.29%-
Gross Profit38.1932.9627.4426.2522.7514.0414.4311.1511.405.66
Operating Income28.3123.4017.6817.0314.446.977.915.125.19-2.03
Net Income24.4720.0511.3311.379.624.655.292.986.60-1.51
Shares Outstanding7.327.247.177.066.836.486.356.356.346.26
Earnings Per Share3.332.731.551.561.320.660.760.430.95-0.24
EPS Growth21.98%76.13%-0.64%18.18%100%-13.16%76.74%-54.74%--
Operating Cash Flow22.2917.7313.1616.3510.616.134.540.93-0.69-0.88
Capital Expenditures----------
Free Cash Flow22.2917.7313.1616.3510.616.134.540.93-0.69-0.88
Cash & Equivalents89.2480.8859.3149.0233.4920.7112.598.508.207.83
Total Debt0.24---------
Net Cash / Debt89.0080.8859.3149.0233.4920.7112.598.508.207.83
Assets12710075.0064.7045.7031.0323.2518.3916.2711.52
Liabilities2.162.507.488.410.890.770.920.931.394.82
Book Value12497.5967.5256.2844.8130.2622.3317.4614.876.70
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Biospecifics Technologies Corp.
Country United States
Employees 7
CEO Joseph Truitt

Stock Information

Ticker Symbol BSTC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BSTC
IPO Date November 14, 1991

Description

BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.